Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Cardiac Rhythm Management Devices Market Size & Share 2026-2035
Report ID: GMI3933
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Cardiac Rhythm Management Devices Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Cardiac Rhythm Management (CRM) Devices Market Size
The cardiac rhythm management (CRM) devices market was valued at USD 15.1 billion in 2025, is valued at USD 16.1 billion in 2026, and is projected to grow at a 6.1% CAGR (2026–2035) to reach USD 27.3 billion by 2035.
Cardiac Rhythm Management Devices Market Key Takeaways
Market Leader: Medtronic led with over 26.2% market share in 2025.
Leading Players: Top 5 players in this market include Medtronic, Abbott, Boston Scientific, ZOLL Medical, Philips, which collectively held a market share of 71.5% in 2025.
The market covers implantable and external devices used to diagnose and manage arrhythmias, conduction abnormalities, and heart failure with an electrophysiological etiology.
Demand is shifting toward connected, lower-complication device architectures while public-access defibrillation programs add a distinct institutional procurement stream. Aging populations, heart failure management, and earlier rhythm-risk identification support implantation volumes, although reimbursement variation and implant-center capacity continue to shape the pace at which clinical need converts into revenue.
GMI Analyst View
Based on input from industry leaders and our review of manufacturer revenue disclosures, we estimate that the global market generated USD 12.70 billion in historic revenue during 2022. We view the subsequent expansion as evidence of a durable procedure-volume base across pacing, defibrillation, and resynchronization therapies.
Cardiac Rhythm Management (CRM) Devices Market Trends, Growth Drivers & GMI Forecast Outlook
Clinical demand is expanding across implantable and external modalities as disease prevalence, pathway modernization, and public-access preparedness programs reinforce different portions of the portfolio. The forecast assumes that technology adoption continues to broaden patient eligibility, while access, reimbursement, and regulatory friction limit full conversion of the clinically addressable population.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Atrial fibrillation adds to the referral funnel for electrophysiology evaluation because it often coexists with structural disease, heart failure, and elevated rhythm-risk profiles. The practical consequence is not merely more monitoring; it is a larger population progressing through risk stratification toward device-based treatment when clinical criteria are met.
Heart failure is particularly consequential for CRT and primary-prevention ICD pathways because therapy decisions depend on coordinated medical management, imaging, and specialist assessment. Connected platforms can also make post-implant follow-up more actionable, strengthening replacement and upgrade demand alongside first-time implants.
Public-access AED programs create a separate procurement mechanism from hospital implant demand. More than 356,000 out-of-hospital cardiac arrests occur annually in the United States, supporting the policy rationale for institutional preparedness and AED placement [4]American Heart Association. "Governor signs life-saving bill requiring cardiac emergency response plans in Texas schools." newsroom.heart.org). Those programs can produce recurring equipment, readiness, and replacement requirements across schools, transport settings, and public venues.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
The principal access constraint is operational as well as financial. ICD and CRT utilization depends on implanting centers, electrophysiology expertise, post-procedure surveillance, and reliable patient follow-up; these requirements remain uneven outside major urban care networks. Clinical eligibility therefore does not automatically translate into realized implantation demand.
Payer scrutiny also affects product mix. Health systems weigh generator longevity, follow-up burden, procedure costs, and the incremental clinical value of premium configurations. For smaller manufacturers, the cost of generating evidence and sustaining post-market obligations can narrow launch options and deepen the advantage of established portfolios.
GMI Analyst View
We see the central forecasting question as the rate at which reimbursement and implantation capacity close the gap between eligible patients and treated patients. We also expect connected care ecosystems to matter increasingly because they influence clinician workflow, follow-up continuity, and replacement timing rather than simply device selection at implantation.
Cardiac Rhythm Management (CRM) Devices Market Segment Analysis
By Product
Pacemakers
The cardiac rhythm management (CRM) devices market pacemaker segment held a 34.0% share in 2025 and is projected to generate USD 8.77 billion by 2035. Leadless pacing, MRI-compatible systems, and conduction-system approaches are changing the category's value proposition from routine rhythm support toward reduced lead-related burden and more tailored implantation pathways.
Implantable Pacemakers
Implantable pacemakers generated USD 4.82 billion in 2025 and are projected to reach USD 8.39 billion by 2035. Leadless and conduction-system pacing adoption expands the clinical relevance of implantable systems, especially where avoiding transvenous leads or preserving vascular access changes the risk-benefit assessment.
External Pacemakers
External pacemakers accounted for a 2.1% share in 2025 and are projected to grow at a 2.0% CAGR (2026–2035). The segment remains tied to acute-care, peri-operative, and bridging use cases. Refresh cycles and uneven access to permanent pacing infrastructure preserve demand, but the category has less exposure to elective technology upgrades.
Defibrillators
Defibrillators generated USD 7.24 billion in 2025 and are projected to represent a 49.6% share by 2035. The category benefits from multiple demand channels: primary-prevention ICD implantation, emergency-care replacement cycles, and legislated AED deployment. That breadth makes defibrillation less dependent on any single care setting.
ICDs
ICDs generated USD 4.38 billion in 2025 and are projected to reach USD 8.31 billion by 2035. Clinical differentiation between transvenous, subcutaneous, and emerging extravascular approaches is becoming more commercially important as physicians match device architecture to pacing needs, anatomy, infection exposure, and long-term lead-management preferences.
S-ICD
S-ICD revenue was USD 1.07 billion in 2025, with an 8.9% CAGR (2026–2035) projected. Avoidance of intravascular leads remains the core differentiator. The category's trajectory depends on how effectively modular pacing-defibrillation options address patients who require both protection from sudden cardiac death and pacing support.
TV-ICD
TV-ICD revenue totaled USD 3.31 billion in 2025 and is forecast to grow at a 5.7% CAGR (2026–2035). Transvenous systems retain a central role where pacing capability and established implant workflows are decisive. Innovation in lead design seeks to defend this installed-base advantage by reducing the complication concerns associated with conventional hardware.
External Defibrillators
External defibrillators generated USD 2.43 billion in 2025 and are projected to reach USD 4.57 billion by 2035. Institutional readiness requirements, hospital emergency workflows, and fleet-management needs support a market dynamic distinct from implantable therapies. Networked device management is becoming a meaningful procurement criterion for large deployments.
AED
AED revenue reached USD 1.74 billion in 2025 and is projected to expand at a 7.5% CAGR (2026–2035). Legislative and organizational preparedness requirements support demand that is less dependent on individual prescribing behavior. Ease of operation, maintenance visibility, and deployment readiness increasingly determine product positioning.
Manual External Defibrillator
Manual external defibrillators held a 4.6% share in 2025 and are projected to grow at a 3.5% CAGR (2026–2035). Demand is anchored in hospital and emergency-response replacement cycles. Clinical familiarity and integration with monitored acute-care environments preserve the category's relevance, though new-site expansion is more limited than in public-access AEDs.
WCD
WCD revenue was USD 423 million in 2025 and is projected to represent a 2.4% share by 2035. Wearable defibrillation serves time-bound risk-management needs rather than permanent therapy. Its opportunity remains tied to referral protocols, reimbursement decisions, and patient adherence during clinically defined observation periods.
CRT Devices
CRT devices accounted for an 18.0% share in 2025 and are projected to generate USD 4.98 billion by 2035. Guideline-driven treatment for electrical dyssynchrony and heart failure provides a stable foundation for CRT. Demand is reinforced when heart-failure programs coordinate diagnosis, medication optimization, implant referral, and remote follow-up.
CRT-D
CRT-D revenue totaled USD 1.90 billion in 2025 and is projected to account for a 13.3% share by 2035. The configuration remains important for patients requiring both resynchronization and defibrillation. Battery performance, remote monitoring capability, and therapy-management functionality shape competitive differentiation.
CRT-P
CRT-P held a 5.4% share in 2025 and is projected to generate USD 1.36 billion by 2035. CRT-P remains relevant where pacing-only resynchronization is clinically appropriate and where payers or providers place greater weight on total treatment cost. Regional practice patterns will continue to influence the balance between CRT-P and CRT-D.
By Application
Arrhythmias
Arrhythmias generated USD 6.04 billion in 2025 and are projected to represent a 41.0% share by 2035. The application spans the broadest set of CRM products, from public-access defibrillation to chronic implanted-device management. Earlier detection through connected monitoring can increase the clinical visibility of patients who require escalation.
CHF
CHF is projected to generate USD 5.73 billion by 2035 and accounted for a 20.0% share in 2025. Heart-failure care pathways underpin CRT utilization and a material portion of ICD demand. Expansion depends on coordinated referral systems that identify patients after pharmacological management has been optimized.
Bradycardia
Bradycardia generated USD 2.56 billion in 2025 and is projected to grow at a 5.1% CAGR (2026–2035). This remains the established foundation of pacing demand. Replacement procedures, MRI-conditional upgrades, and leadless conversion opportunities sustain the category even where first-time implant penetration is mature.
Tachycardia
Tachycardia is projected to account for a 17.0% share by 2035 and grow at a 6.7% CAGR (2026–2035). ICD therapy and broader risk stratification support above-market momentum. Adoption will depend on the ability of clinicians to identify patients who benefit from protection before a major arrhythmic event occurs.
By End Use
Hospitals
Hospitals held a 67.0% share in 2025 and are projected to generate USD 17.74 billion by 2035. Hospitals remain the principal setting for complex ICD and CRT procedures because they combine electrophysiology infrastructure, specialist support, and post-implant monitoring capacity. Their role remains durable even as selected lower-acuity procedures migrate outward.
Cardiac Care Centers
Cardiac care centers are projected to hold a 20.0% share by 2035 and generated USD 2.86 billion in 2025. Dedicated centers can concentrate electrophysiology expertise and standardize same-day protocols. Their growth depends on health systems' willingness to shift suitable procedures into specialized pathways without compromising follow-up continuity.
Ambulatory Surgical Centers
Ambulatory surgical centers accounted for an 11.0% share in 2025 and are projected to generate USD 3.27 billion by 2035. ASCs benefit where reimbursement, physician practice models, and patient-selection protocols support outpatient implantation. The setting is most relevant to less complex procedures and can alter channel relationships as site-of-care economics evolve.
GMI Analyst View
We expect product competition to be defined increasingly by the ability to reduce long-term lead-related burden while preserving the therapeutic flexibility clinicians need. In our view, public-access defibrillation and specialized outpatient pathways will create commercial opportunities that differ materially from the traditional implant-centered model.
Cardiac Rhythm Management (CRM) Devices Market Regional Analysis
North America Cardiac Rhythm Management (CRM) Devices Market Analysis
The North America Cardiac Rhythm Management (CRM) Devices Market generated USD 6.04 billion in 2025 and is projected to reach USD 10.28 billion by 2035. Dense electrophysiology infrastructure, established payer coverage, and a deep replacement base support the region. Growth is increasingly shaped by platform upgrades, outpatient migration for suitable procedures, and institutional AED programs.
U.S.
The U.S. generated USD 5.43 billion in 2025 and is projected to hold a 33.7% share by 2035. Medicare coverage, commercial insurance, and broad access to implanting centers make the country the principal commercial market for most CRM modalities. The shift toward lower-cost care settings may reshape purchasing and service models without materially reducing device need.
Canada
Canada is projected to generate USD 1.09 billion by 2035 and held a 4.0% share in 2025. Provincial coverage provides a stable demand base, while tender structures and rural-access limitations influence procedure timing and product selection. Suppliers must navigate centralized procurement alongside concentrated specialist capacity.
Europe Cardiac Rhythm Management (CRM) Devices Market Analysis
Europe held a 28.0% share in 2025 and is projected to generate USD 7.27 billion by 2035. Clinical guidelines and national reimbursement frameworks support predictable use of indicated therapy, but MDR requirements and budget discipline increase the importance of evidence generation, local market access, and cost-effective portfolio design.
Germany
Germany generated USD 761 million in 2025 and is projected to reach USD 1.33 billion by 2035. Its dense cardiac-center network and established reimbursement mechanisms make Germany a critical European market for novel device adoption. The country remains strategically important for manufacturers seeking early clinical experience with new pacing and defibrillation platforms.
UK
The UK is projected to hold a 4.0% share by 2035 and grow at a 5.5% CAGR (2026–2035). NHS procurement creates a cost-conscious but relatively steady environment. Capacity expansion in regional cardiac networks can improve access, while centralized purchasing raises the premium on clinical and economic evidence.
France
France generated USD 549 million in 2025 and is projected to hold a 3.4% share by 2035. National reimbursement and tender processes support guideline-based care while constraining price realization. Heart-failure management initiatives and tertiary-center monitoring capabilities remain important demand drivers.
Italy
Italy is projected to generate USD 802 million by 2035 and held a 3.1% share in 2025. Decentralized regional healthcare administration creates variation in reimbursement and procurement timing. Suppliers must address uneven uptake between advanced northern cardiac centers and less-penetrated areas.
Spain
Spain generated USD 338 million in 2025 and is projected to grow at a 5.9% CAGR (2026–2035). Broad public coverage supports underlying demand, while implanting-center capacity determines local procedure access. Expanding electrophysiology infrastructure should support adoption across pacing, ICD, and CRT pathways.
Netherlands
The Netherlands held a 1.7% share in 2025 and is projected to generate USD 442 million by 2035. Managed care and structured disease-management programs create consistent referral pathways. The market's emphasis on coordinated follow-up favors connected platforms that fit established remote-monitoring practices.
Asia Pacific Cardiac Rhythm Management (CRM) Devices Market Analysis
Asia Pacific generated USD 3.32 billion in 2025 and is projected to hold a 24.8% share by 2035. Aging populations, expanded coverage, and new cardiac-care capacity are broadening access across the region. Local manufacturing and price-sensitive procurement will be central to determining the balance between multinational and domestic suppliers.
China
China generated USD 1.26 billion in 2025 and is projected to represent a 9.1% share by 2035. Domestic manufacturing development and hospital procurement policies are altering competitive conditions. Scale, localization, and compatibility with the tiered reimbursement environment are increasingly important to market participation.
Japan
Japan is projected to generate USD 1.60 billion by 2035 and held a 5.9% share in 2025. A large older population and broad national insurance coverage support pacing demand. Regulatory review requirements and conservative clinical adoption patterns can moderate the speed at which newer architectures displace established systems.
India
India generated USD 498 million in 2025 and is projected to grow at an 11.0% CAGR (2026–2035). Expansion of insurance access and electrophysiology capacity is enlarging the treated patient pool. Affordable product offerings and distribution beyond metropolitan centers will determine how much of the country's clinical need becomes commercial demand.
South Korea
South Korea held a 2.2% share in 2025 and is projected to grow at a 7.5% CAGR (2026–2035). Comprehensive coverage and advanced hospital infrastructure support use of sophisticated implantable systems. Regulatory alignment with international practice can reduce the delay between global device availability and domestic adoption.
Australia
Australia generated USD 232 million in 2025 and is projected to grow at a 5.8% CAGR (2026–2035). Efficient device-market access and established cardiac-care infrastructure support demand. Public AED requirements add a visible institutional procurement component to the broader implant-focused market.
Latin America Cardiac Rhythm Management (CRM) Devices Market Analysis
Latin America held a 5.0% share in 2025 and is projected to grow at a 6.8% CAGR (2026–2035). The region's opportunity is anchored in large population centers and a gradual buildout of specialist care. Currency volatility, import dependence, and uneven reimbursement remain material constraints, especially for higher-cost implantable systems.
Brazil
Brazil is projected to generate USD 714 million by 2035 and held a 2.4% share in 2025. Public access supports core pacing demand, while private and supplemental coverage contributes disproportionately to ICD and CRT uptake. Regional partnerships can improve availability beyond the country's largest urban markets.
Mexico
Mexico generated USD 212 million in 2025 and is projected to grow at a 6.5% CAGR (2026–2035). Social-security coverage supports indicated pacing procedures, while private networks play a larger role in advanced implantable therapies. Supplier reach and specialist capacity will influence the pace of expansion.
Argentina
Argentina held a 0.7% share in 2025 and is projected to generate USD 184 million by 2035. Import restrictions and macroeconomic instability can interrupt supply and delay procurement. Basic pacing demand has greater resilience than premium ICD and CRT adoption, which remains more exposed to private-payment conditions.
Middle East & Africa Cardiac Rhythm Management (CRM) Devices Market Analysis
Middle East & Africa is projected to generate USD 1.51 billion by 2035 and grow at a 7.2% CAGR (2026–2035). The region contains sharply different market conditions: Gulf investment supports advanced care infrastructure, while limited implant capacity constrains utilization in many African settings. Channel development and specialist training are decisive commercial variables.
Saudi Arabia
Saudi Arabia held a 1.5% share in 2025 and is projected to grow at a 7.5% CAGR (2026–2035). Healthcare investment is expanding electrophysiology capacity and strengthening referral pathways. Premium-device demand should benefit where new cardiac centers develop the staffing and follow-up capabilities required for complex implants.
UAE
The UAE generated USD 189 million in 2025 and is projected to reach USD 379 million by 2035. Comprehensive private coverage and specialist care hubs support premium-device adoption. The country's regional referral role can reinforce demand for advanced electrophysiology procedures beyond its resident population.
South Africa
South Africa held a 1.0% share in 2025 and is projected to grow at a 5.6% CAGR (2026–2035). Private hospital networks account for much of the advanced implantable-device opportunity, while public-sector resource limitations restrict broader access. Future coverage expansion could improve pacing availability, but infrastructure remains a key constraint.
GMI Analyst View
We believe regional growth will depend less on disease burden alone than on the practical ability to convert need into implant procedures and managed follow-up. North America remains structurally advantaged, while Asia Pacific and selected Middle Eastern markets offer the clearest opportunity for capacity-led expansion and portfolio localization.
Cardiac Rhythm Management (CRM) Devices Market Share & Competitive Landscape
The cardiac rhythm management (CRM) devices market share structure is concentrated, with the top five companies collectively holding approximately 71.5% in 2025. Scale matters because portfolio breadth, evidence generation, regulatory support, clinician training, and remote-monitoring infrastructure are increasingly interdependent competitive assets.
Medtronic held a 26.2% share in 2025. Its position is supported by breadth across pacing, ICD, and CRT platforms, alongside a connected-care ecosystem that can strengthen physician workflow integration. Its OmniaSecure defibrillation lead received FDA approval in April 2025, extending the company's focus on miniaturized transvenous hardware [5]Medtronic plc. "Medtronic receives FDA approval for OmniaSecure defibrillation lead." news.medtronic.com.
Abbott held a 16.3% share in 2025. The company's leadless pacing and electrophysiology capabilities position it across diagnosis and therapy, while conduction-system pacing development could broaden its role in evolving ICD and CRT treatment pathways.
Boston Scientific held a 15.7% share in 2025. Its S-ICD platform, pacing technologies, and modular rhythm-management strategy position the company for a market that increasingly values lead avoidance and system flexibility. Its expanded INGEVITY+ pacing lead indication reinforces its physiologic-pacing position in Europe [6]Boston Scientific Corporation. "Boston Scientific receives CE mark for expanded indication of INGEVITY+ Pacing Leads." news.bostonscientific.eu.
ZOLL Medical retains a differentiated role through wearable, public-access, and acute-care defibrillation. That focus gives it exposure to institutional procurement cycles that differ from the implant-driven competition among the largest CRM portfolio providers.
Philips competes principally through emergency-care and AED offerings. Connected fleet management, readiness alerts, and maintenance oversight are becoming important differentiators as organizations manage larger distributed AED estates.
BIOTRONIK, LivaNova, MicroPort, Stryker, Nihon Kohden, SCHILLER, defibtech, and other regional or niche participants sustain competition through specialized product portfolios, local channels, and focused clinical segments. MicroPort's strategic combination of CRM and structural-heart capabilities illustrates the importance of broader cardiovascular-care positioning as providers seek integrated pathways.
Recent Industry Developments
Boston Scientific received CE Mark in September 2025 for an expanded indication of its INGEVITY+ Pacing Leads for conduction-system pacing and left bundle branch area sensing. The development strengthens the company's access to the growing physiologic-pacing segment in Europe [6]Boston Scientific Corporation. "Boston Scientific receives CE mark for expanded indication of INGEVITY+ Pacing Leads." news.bostonscientific.eu.
MicroPort CardioFlow and MicroPort CRM completed a strategic merger in December 2025, combining structural-heart and rhythm-management capabilities into a broader heart-failure care platform [7]MicroPort Scientific Corporation. "MicroPort CardioFlow and CRM Merge to Build Global Platform for Heart Failure Care." microport.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →